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1. INTRODUCTION 
The human alkaline phosphatases (ALPS) are 
membrane-bound glycoproteins that occur in dif- 
ferent forms in different tissues. Their protein 
moieties are coded for at least 3 gene loci; one 
for placental ALP (ALP,), at least one for the in- 
testinal ALPS (adult and fetal) and at least one for 
liver/bone/kidney ALPS [ 11. We have been in- 
vestigating the immunological differences and 
similarities of these various ALPS using 
monoclonal antibodies. Here, we describe studies 
aimed at defining immunologic epitopes on the 
surface of the intestinal ALPS using a series of 7 
monoclonal antibodies all of which bind to both 
adult (ALP& and fetal (ALPFI) forms of human 
intestinal ALP. To do this we define an additivity 
value (ADD): the amount of a labeled antibody 
bound to the enzyme after prior saturation with a 
different unlabeled antibody, calculated as a 
percentage of label bound to the enzyme without 
prior saturation by the other antibody. Low ADD 
values imply that the two antibodies tested bind to 
determinants that are spatially close on the enzyme 
surface, if not identical. High ADD values imply 
that the determinants recognized by the two an- 
tibodies are well separated. 
* To whom correspondence should be addressed 
Our findings suggest hat the 7 antibodies are 
directed to determinants in 3 distinct epitopes on 
both adult and fetal intestinal ALP; 3 in one 
epitope, 3 in another, and one in a third epitope. 
Each of the epitopes are also represented on ALP,, 
though one appears to have diverged structurally 
in evolution to a greater degree than the others. 
2. MATERIALS AND METHODS 
2.1. ALP extracts 
Aqueous solutions containing ALPAI, ALPFI 
and ALPp were prepared and assayed as in [2]. 
2.2. Monoclonal antibodies 
The 7 monoclonal antibodies used were: 
ALP~t/Sp2/38, ALP&Sp2/37, ALPrt/Sp2/36, 
ALP~t/Sp2/41, ALPdSp2/39, ALPp/Sp2/5 and 
ALP-D98/Sp2/22. Their production, characteri- 
zation, and the preparation of antibody-rich 
mouse ascites fluids has been described [3-61. For 
simplicity we will refer to the different antibodies 
in the rest of this paper simply by their numerical 
listing, e.g., ab38, ab36, etc. The antibodies were 
purified from ascites fluids using a Staphylococcus 
aureus protein-A conjugated Sepharose 4B col- 
umn. Polyclonal antiserum to intestinal ALP was 
made in rabbits as described [3]. 
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2.3. ‘251-labeling of monoclonal antibodies 
Radioiodination using 1251 and Chloramin T, as 
in [7]. 
2.4. Determination of antibody concentration 
required to saturate immobilized ALP 
100~1 rabbit anti-human intestinal ALP 
polyclonal antiserum at a dilution of 114000 was 
applied per well of a PVC Cooke 96-well microtiter 
plate. After 2 h at room temperature, the plate was 
emptied and the wells filled with blocking buffer, 
0.67% bovine serum albumin (BSA) in phosphate- 
buffered saline (PBS), pH 7.2, and incubated at 
room temperature for 30 min. After emptying the 
wells, 50,ul human intestinal ALP (ALPAI or 
ALP& at a concentration of 500 mIU/ml in 0.5% 
BSA in PBS, pH 7.2, was added per well and in- 
cubated overnight at 4°C. The wells were washed 
twice with 0.5% BSA in PBS to remove any un- 
bound ALP. Serial dilutions of purified ascites 
fluid antibody were then applied and the amount 
of antibody bound determined with peroxidase 
labeled rabbit anti-mouse immunoglobulin serum 
as in [6]. A concentration of antibody at least ten 
times the maximum required to produce saturation 
as indicated by this test, was used for the ADD 
assay. 
2.5. Additivity (ADD) assay 
Enzyme was immobilized in a 96well microtiter 
plate as described above for determining antibody 
saturating concentration. 50~1 of a monoclonal 
antibody at a saturating concentration in 0.5% 
BSA in PBS was added per well and incubated at 
4°C for 2 h. This was followed by the addition of 
50~1 of an 12?-labeled monoclonal antibody in 
0.5% BSA in PBS per well (approximately 2 x 
lo5 cpm per well), and the plate was incubated at 
4°C for 2 h. The content of the wells was removed 
by vacuum, and the wells were washed 6 times with 
cold water and dried. The wells were then cut free 
of the plate and counted in a gamma counter. Six 
wells were run with each combination. Twelve 
wells were used for determining the control bin- 
ding (i.e., without saturating antibody) and 12 
wells for determining background (i.e., without 
ALP). The entire series was repeated 4 times giving 
a total of 24 determinations ior each combination. 
The means of the values were calculated and used 
in the following equation for determining ADD: 
ADD = % control binding = 
[(cpm in the presence of saturating antibody - 
background)/(cpm in the absence of saturating 
antibody - background)] x 100 
3. RESULTS 
The experimental design was to test each pair of 
antibodies by first saturating a standardized 
amount of immobilized enzyme (either ALPAI or 
ALPrr) with one antibody of a pair, then applying 
the other antibody labeled with 125I. The amount 
of 1251 bound was then determined. Each pair of 
antibodies was examined reciprocally. One 
member of the pair first served as the saturating 
antibody and then in the reciprocal experiment 
served as the 1251-labeled antibody. Since the two 
members of a pair of antibodies are applied 
separately and not simultaneously to the enzyme, 
the method is not strictly speaking a competition 
assay. We therefore refer to the binding of a label- 
ed antibody after prior saturation of the enzyme 
with the other antibody, as an additivity value 
(ADD). 
Six of the ‘251-labeled antibodies were able to 
bind to immobilized ALP in the absence of 
saturating cold antibody (i.e., control binding) 
with counts of between 2000 and 5000 cpm. One 
antibody (ab37) however gave much lower bin- 
ding, only about 15% of the cpm obtained with the 
other labeled antibodies. Since unlabeled ab37 
could bind to the enzyme as well as any of the 
others in saturation studies (not shown) it is likely 
that iodination of ab37 had affected the antibody 
binding site, possibly due to the presence of a 
tyrosine residue in this region. The level of binding 
obtained with this labeled antibody would not be 
appropriate for use in further analysis, so lz51- 
labeled ab37 has been excluded from determina- 
tions of ADDS. However, the use of unlabeled 
ab37 in combination with the other labeled an- 
tibodies has been included. 
To check the efficacy of saturation, each 1251- 
labeled antibody was tested for binding after prior 
saturation of immobilized ALP with the same 
unlabeled antibody. In all cases the ADD values 
were less than 1%) indicating that saturation was 
effectively complete. 
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Fig.1. Correlation of ADD values for ALPFI and ALPAI with 6 monoclonal antibodies. 
Fig.1 shows ADD values for ALPAI and ALPrr 
obtained with each pair of antibodies. There is a 
close correlation (r = 0.99) indicating that all the 
determinants for these different antibodies are pre- 
sent in both ALPAI and ALPrr. In view of this 
result, mean ADD values of an antibody for 
ALPA~ and ALPrr have been used in further 
analysis of the data. 
Table 1 shows the reciprocal ADD values for 
each of the 15 antibody pairs where reciprocal tests 
were possible. In the case of ab37, only the values 
when this was used as the unlabeled antibody are 
shown. In general, there is a good correlation be- 
tween the ADD values in reciprocal tests on the 
pairs of antibody (r = 0.87). In a few cases there 
is a relatively small deviation from equality for the 
two values in the reciprocal tests. This may be due 
to appreciable differences in avidity between the 
two antibodies for the enzyme or to experimental 
296 
error. The SDS of the individual ADD values for 
each of the antibody combinations varied between 
0.5 and 5. 
To examine the topological relationships of the 
various determinants defined by the different an- 
tibodies, we categorized the ADD values shown in 
table 1 into 4 classes as follows: (A) O-19; (B) 
20-39; (C) 40-59; (D) 60 or greater. Fig.2 il- 
lustrates the presumptive topological relationships 
of the antigenic determinants on the surface of the 
intestinal ALP molecules recognized by the dif- 
ferent antibodies using this classification. Where 
reciprocal tests on a pair of antibodies were possi- 
ble the two ADD classes are shown. In the case of 
ab37, only the ADD values where this was used as 
a saturating antibody are shown. ADD values fall- 
ing into the lowest class, AA or A, suggest hat the 
antigenic determinants recognized by a pair of an- 
tibodies lie close together on the enzyme surface 
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Table 1 
ADD values for different combinations of 7 antibodies with intestinal ALP (data for ALPAI and ALPn combined) 
‘=I_ Unlabeled 
labeled saturating 
antibody antibody 
(a) Reciprocal ADD tests 
ab5 ab22 
ab22 ab5 
ab39 ab22 
ab22 ab39 
ab39 ab5 
ab5 ab39 
ab4 1 ab22 
ab22 ab41 
ab4 1 ab5 
ab5 ab41 
ab39 ab41 
ab41 ab39 
ab22 ab36 
ab36 ab22 
ab36 ab5 
ab5 ab36 
(b) One way ADD tests 
ab38 ab37 
ab41 ab37 
ab39 ab37 
ADD 
value 
76.4 
39.1 
4.2 
5.8 
40.8 
62.5 
116.3 
93.2 
111.3 
80.5 
93.2 
86.5 
13.9 
53.5 
5.7 
3.7 
51.9 
106.8 
6.2 
‘251_ Unlabeled 
labeled saturating 
antibody antibody 
ab39 ab36 
ab36 ab39 
ab41 ab36 
ab36 ab41 
ab22 ab38 
ab38 ab22 
ab5 ab38 
ab38 ab5 
ab39 ab38 
ab38 ab39 
ab41 ab38 
ab38 ab4 1 
ab36 ab38 
ab38 ab36 
ab5 ab37 
ab36 ab37 
ab22 ab37 
ADD 
value 
24.6 
35.1 
24.8 
22.3 
93.5 
67.5 
4.5 
5.1 
21.5 
24.1 
27.3 
14.0 
19.3 
0.2 
77.9 
60.0 
5.8 
ab39 ab37 ab22 ab41 ab38 ab36 ab5 
ab38 - 
ab36 AA - 
ab5 AA M - 
ab39 BB BB CD 
ab37 C D D A - 
ab22 DD AC DB MA - 
ab41 BA BB DD DD D DD II 
Fig.2. ADD levels grouped into four classes A, B, C and D as described in the text, for different antibody combinations 
with intestinal ALP (ALPAI and ALPn combined). 
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and may possibly overlap or be identical. Higher 
ADD values (e.g., BB, BC, CD, etc.) imply that 
the two determinants are further apart. Fig.2 sug- 
gests that the antibodies can be divided into 3 
groups. In group 1 ab38, ab36 and ab5 give low 
ADD values (AA) with each other but higher 
values with the 4 other antibodies. Group 2 (ab39, 
ab37 and ab22) give low ADD values (AA or A) 
with each other but high values with the other an- 
tibodies. Group 3, which includes only one an- 
tibody (ab41), is distinct from either of the other 
two groups. 
4. DISCUSSION 
In general the experimental design, which in- 
volves the sequential application of a saturating 
antibody followed by 1251-labeled antibody to the 
immobilized enzyme, is similar to that used in 
other studies of the same sort, and appears to pro- 
vide a satisfactory and systematic approach to the 
topological analysis of antigenic determinants on 
enzymes. If the two members of a pair of an- 
tibodies have the same avidity for the enzyme, then 
one expects the ADD values in the reciprocal tests 
to be equal, apart from experimental error. Signifi- 
cant deviations from equality would imply avidity 
differences which might be confounded with the 
effects of topological separation. With the set of 
antibodies studied here, such avidity differences 
that may exist do not appear to have influenced the 
ADD values sufficiently to invalidate their use as 
topological markers. 
In occasional cases r2’I-labeling markedly 
reduces the binding of the antibody to the enzyme 
(1 out of the 7 antibodies used here). This is pro- 
bably due to the insertion of the 12’1 into tyrosine 
residues close to the binding site of the antibody. 
If so, it precludes the use of such labeled an- 
tibodies in ADD assays, though the antibody can 
still be used as a saturating antibody. This difficul- 
ty might in principle be dealt with by some other 
method of antibody labeling, e.g., labeling with 
peroxidase. 
The findings indicate that the antibodies fall into 
three separate groups which are distinguishing dif- 
ferent epitopes on the enzyme surface. Epitope 1 
contains determinants for ab38, ab36 and ab5. 
Epitope 2 contains determinants for ab39, ab37 
and ab22. Epitope 3 contains the determinant for 
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ab41. The epitopes appear to be well separated on 
the enzyme surface, though epitope 3 may be 
somewhat closer to epitope 1 than epitope 2. 
It is of interest to relate these findings to other 
information about the characteristics of the 
various antibodies. As noted in section 3, all of the 
determinants recognized by this set of antibodies 
occur on both ALP*r and ALPrr. Antibodies 
ab38, ab36, ab5 (epitope l), ab22 (epitope 2) and 
ab41 (epitope 3) have in other studies also been 
shown to bind to ALPp [3,4,5]. ALPp is known to 
be structurally distinct from the intestinal ALPS 
and its protein moiety to be encoded by a separate 
gene locus. It has been suggested that ALPp and 
the intestinal ALPS arose in evolution by duplica- 
tion of a common ancestral gene, and that they 
subsequently diverged in structure by point muta- 
tions [I]. The present results suggest hat each of 
the three epitopes are represented on the placental 
ALP molecule though presumably with structural 
modifications. The fact that of the three antibodies 
recognizing determinants in epitope 2, two do not 
cross-react with placental ALP (ab37 and ab39), 
suggests that this epitope may have been less con- 
served structurally than the other epitopes. 
Placental ALP, unlike the intestinal ALPS, is 
known to be genetically highly polymorphic, with 
three common alleles found in most human 
populations. In various studies using monoclonal 
antibodies generated against placental ALP it has 
been shown that the products of the three common 
alleles can in a number of cases be discriminated by 
monoclonal antibodies [6,8]. Of the series of an- 
tibodies discussed here, one (ab41) has been found 
to give significantly reduced binding with the pro- 
duct of the type 3 allele than with the product of 
either the type 1 and type 2 alleles [3]. This implies 
that the antibody is directed to a determinant on 
the ALP molecule whose structure was altered by 
the mutation giving rise to the type 3 allele. The 
present results indicate that this mutation must lie 
in the DNA region coding for epitope 3. 
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